Cytophilic antibodies against key plasmodium falciparum blood stage antigens contribute to protection against clinical malaria in a high transmission region of eastern India

Journal of Infectious Diseases

Volumn 218, Issue 6, 2018, Pages 956-965

  Kana, Ikhlaq Hussain ^a,b   Garcia Senosiain, Asier ^b   Singh, Susheel K ^a,b   Tiendrebeogo, Régis Wendpayangde ^a,b   Chourasia, Bishwanath Kumar ^a,b   Malhotra, Pawan ^c   Sharma, Surya K ^d   Das, Manoj K ^e   Singh, Subhash ^f   Adu, Bright ^g   Theisen, Michael ^a,b  

^a STATENS SERUM INSTITUT   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^d NATIONAL INSTITUTE OF MALARIA RESEARCH   (India)

^e National Institute of Malaria Research   (India)

^f CSIR INDIAN INSTITUTE OF INTEGRATIVE MEDICINE   (India)

^g University of Ghana   (Ghana)

Author keywords

Merozoites antigens; Naturally acquired immunity; Opsonic phagocytosis

Indexed keywords

IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G3 ANTIBODY; RECOMBINANT PROTEIN; PROTOZOON ANTIBODY;

ADAPTIVE IMMUNITY; ADOLESCENT; ADULT; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CHILD; COHORT ANALYSIS; ENDEMIC DISEASE; FEMALE; HUMAN; INCIDENCE; INDIA; INFECTION PREVENTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; NATURALLY ACQUIRED IMMUNITY; PARASITE TRANSMISSION; PHAGOCYTOSIS; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; BLOOD; DRUG EFFECT; IMMUNOLOGY; MEROZOITE; MIDDLE AGED; PRESCHOOL CHILD; YOUNG ADULT;

ADAPTIVE IMMUNITY; ADOLESCENT; ADULT; ANTIBODIES, PROTOZOAN; CHILD; CHILD, PRESCHOOL; ENDEMIC DISEASES; FEMALE; HUMANS; INDIA; LONGITUDINAL STUDIES; MALARIA, FALCIPARUM; MALE; MEROZOITES; MIDDLE AGED; PHAGOCYTOSIS; PLASMODIUM FALCIPARUM; YOUNG ADULT;

EID: 85054982569     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiy258     Document Type: Article

References (50)

1. World Health Organization. World Malaria Report 2017. http://www.who.int/malaria/publications/world-malaria-report-2017/report/en/. Accessed 29 November 2017.
2. Sharma RK, Thakor HG, Saha KB, Sonal GS, Dhariwal AC, Singh N. Malaria situation in India with special reference to tribal areas. Indian J Med Res 2015; 141:537-45.
3. Hay SI, Gething PW, Snow RW. India's invisible malaria burden. Lancet 2010; 376:1716-7.
4. Wangdi K, Gatton ML, Kelly GC, Banwell C, Dev V, Clements AC. Malaria elimination in India and regional implications. Lancet Infect Dis 2016; 16:e214-24.
5. Calderaro A, Piccolo G, Gorrini C, et al. Accurate identification of the six human Plasmodium spp. causing imported malaria, including Plasmodium ovale wallikeri and Plasmodium knowlesi. Malar J 2013; 12:321.
6. Cohen S, McGregor IA, Carrington S. Gamma-globulin and acquired immunity to human malaria. Nature 1961; 192:733-7.
7. McGregor IA, Carrington SP, Cohen S. Treatment of East African P. falciparum malaria with West African gammaglobulin. Trans R Soc Trop Med Hyg 1963; 57:170-5.
8. Crompton PD, Kayala MA, Traore B, et al. A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proc Natl Acad Sci U S A 2010; 107:6958-63.
9. Kana IH, Adu B, Tiendrebeogo RW, Singh SK, Dodoo D, Theisen M. Naturally acquired antibodies target the glutamate-rich protein on intact merozoites and predict protection against febrile malaria. J Infect Dis 2017; 215:623-30.
10. Richards JS, Arumugam TU, Reiling L, et al. Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development. J Immunol 2013; 191:795-809.
11. Beeson JG, Drew DR, Boyle MJ, Feng G, Fowkes FJ, Richards JS. Merozoite surface proteins in red blood cell invasion, immunity and vaccines against malaria. FEMS Microbiol Rev 2016; 40:343-72.
12. Fowkes FJ, Richards JS, Simpson JA, Beeson JG. The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: a systematic review and meta-analysis. PLoS Med 2010; 7:e1000218.
13. Murungi LM, Kamuyu G, Lowe B, et al. A threshold concentration of anti-merozoite antibodies is required for protection from clinical episodes of malaria. Vaccine 2013; 31:3936-42.
14. Osier FH, Mackinnon MJ, Crosnier C, et al. New antigens for a multicomponent blood-stage malaria vaccine. Sci Transl Med 2014; 6:247ra102.
15. Dechavanne C, Sadissou I, Bouraima A, et al. Acquisition of natural humoral immunity to P. falciparum in early life in Benin: impact of clinical, environmental and host factors. Sci Rep 2016; 6:33961.
16. Dodoo D, Theisen M, Kurtzhals JA, et al. Naturally acquired antibodies to the glutamate-rich protein are associated with protection against Plasmodium falciparum malaria. J Infect Dis 2000; 181:1202-5.
17. Meraldi V, Nebié I, Tiono AB, et al. Natural antibody response to Plasmodium falciparum Exp-1, MSP-3 and GLURP long synthetic peptides and association with protection. Parasite Immunol 2004; 26:265-72.
18. Soe S, Theisen M, Roussilhon C, Aye KS, Druilhe P. Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein. Infect Immun 2004; 72:247-52.
19. Duncan CJ, Hill AV, Ellis RD. Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy? Hum Vaccin Immunother 2012; 8:706-14.
20. Boyle MJ, Reiling L, Feng G, et al. Human antibodies fix complement to inhibit Plasmodium falciparum invasion of erythrocytes and are associated with protection against malaria. Immunity 2015; 42:580-90.
21. Roestenberg M, McCall M, Mollnes TE, et al. Complement activation in experimental human malaria infection. Trans R Soc Trop Med Hyg 2007; 101:643-9.
22. Bouharoun-Tayoun H, Attanath P, Sabchareon A, Chongsuphajaisiddhi T, Druilhe P. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J Exp Med 1990; 172:1633-41.
23. Osier FH, Feng G, Boyle MJ, et al. Opsonic phagocytosis of Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of protection against malaria. BMC Med 2014; 12:108.
24. Khusmith S, Druilhe P, Gentilini M. Enhanced Plasmodium falciparum merozoite phagocytosis by monocytes from immune individuals. Infect Immun 1982; 35:874-9.
25. Celada A, Cruchaud A, Perrin LH. Opsonic activity of human immune serum on in vitro phagocytosis of Plasmodium falciparum infected red blood cells by monocytes. Clin Exp Immunol 1982; 47:635-44.
26. Joos C, Marrama L, Polson HE, et al. Clinical protection from falciparum malaria correlates with neutrophil respiratory bursts induced by merozoites opsonized with human serum antibodies. PLoS One 2010; 5:e9871.
27. Adu B, Dodoo D, Adukpo S, et al. Fc γ receptor IIIB (FcγRIIIB) polymorphisms are associated with clinical malaria in Ghanaian children. PLoS One 2012; 7:e46197.
28. Adu B, Jepsen MP, Gerds TA, et al. Fc gamma receptor 3B (FCGR3B-c.233CA-rs5030738) polymorphism modifies the protective effect of malaria specific antibodies in Ghanaian children. J Infect Dis 2014; 209:285-9.
29. Tiendrebeogo RW, Adu B, Singh SK, et al. Antibodydependent cellular inhibition is associated with reduced risk against febrile malaria in a longitudinal cohort study involving Ghanaian children. Open Forum Infect Dis 2015; 2:ofv044.
30. Hill DL, Eriksson EM, Li Wai Suen CS, et al. Opsonising antibodies to P. falciparum merozoites associated with immunity to clinical malaria. PLoS One 2013; 8:e74627.
31. Theisen M, Soe S, Oeuvray C, et al. The glutamate-rich protein (GLURP) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro. Infect Immun 1998; 66:11-7.
32. Chiu CY, Hodder AN, Lin CS, et al. Antibodies to the Plasmodium falciparum proteins MSPDBL1 and MSPDBL2 opsonize merozoites, inhibit parasite growth, and predict protection from clinical malaria. J Infect Dis 2015; 212:406-15.
33. Das MK, Prajapati BK, Tiendrebeogo RW, et al. Malaria epidemiology in an area of stable transmission in tribal population of Jharkhand, India. Malar J 2017; 16:181.
34. Jogdand PS, Singh SK, Christiansen M, Dziegiel MH, Singh S, Theisen M. Flow cytometric readout based on Mitotracker Red CMXRos staining of live asexual blood stage malarial parasites reliably assesses antibody dependent cellular inhibition. Malar J 2012; 11:235.
35. Hill DL, Eriksson EM, Carmagnac AB, et al. Efficient measurement of opsonising antibodies to Plasmodium falciparum merozoites. PLoS One 2012; 7:e51692.
36. Skogstrand K, Thorsen P, Nørgaard-Pedersen B, Schendel DE, Sørensen LC, Hougaard DM. Simultaneous measurement of 25 inflammatory markers and neurotrophins in neonatal dried blood spots by immunoassay with xMAP technology. Clin Chem 2005; 51:1854-66.
37. Singh SK, Tiendrebeogo RW, Chourasia BK, Kana IH, Singh S, Theisen M. Lactococcus lactis provides an efficient platform for production of disulfide-rich recombinant proteins from Plasmodium falciparum. Microb Cell Fact 2018; 17:55.
38. Jepsen MP, Röser D, Christiansen M, et al. Development and evaluation of a multiplex screening assay for Plasmodium falciparum exposure. J Immunol Methods 2012; 384:62-70.
39. Rono J, Osier FH, Olsson D, et al. Breadth of anti-merozoite antibody responses is associated with the genetic diversity of asymptomatic Plasmodium falciparum infections and protection against clinical malaria. Clin Infect Dis 2013; 57:1409-16.
40. Osier FH, Fegan G, Polley SD, et al. Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect Immun 2008; 76:2240-8.
41. Hill DL, Wilson DW, Sampaio NG, et al. Merozoite antigens of Plasmodium falciparum elicit strain-transcending opsonizing immunity. Infect Immun 2016; 84:2175-84.
42. Theisen M, Roeffen W, Singh SK, et al. A multi-stage malaria vaccine candidate targeting both transmission and asexual parasite life-cycle stages. Vaccine 2014; 32:2623-30.
43. Baird JK. Host age as a determinant of naturally acquired immunity to Plasmodium falciparum. Parasitol Today 1995; 11:105-11.
44. Theisen M, Adu B, Mordmüller B, Singh S. The GMZ2 malaria vaccine: from concept to efficacy in humans. Expert Rev Vaccines 2017; 16:907-17.
45. Balam S, Olugbile S, Servis C, et al. Plasmodium falciparum merozoite surface protein 2: epitope mapping and fine specificity of human antibody response against non-polymorphic domains. Malar J 2014; 13:510.
46. Osier FH, Murungi LM, Fegan G, et al. Allele-specific antibodies to Plasmodium falciparum merozoite surface protein-2 and protection against clinical malaria. Parasite Immunol 2010; 32:193-201.
47. Conway DJ, Cavanagh DR, Tanabe K, et al. A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses. Nat Med 2000; 6:689-92.
48. Greenhouse B, Ho B, Hubbard A, et al. Antibodies to Plasmodium falciparum antigens predict a higher risk of malaria but protection from symptoms once parasitemic. J Infect Dis 2011; 204:19-26.
49. Richards JS, Stanisic DI, Fowkes FJ, et al. Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from malaria and high-density parasitemia. Clin Infect Dis 2010; 51:e50-60.
50. John CC, Moormann AM, Pregibon DC, et al. Correlation of high levels of antibodies to multiple pre-erythrocytic Plasmodium falciparum antigens and protection from infection. Am J Trop Med Hyg 2005; 73:222-8.